Literature DB >> 29803753

Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation.

Eric Huselton1, Michael Slade1, Kathryn M Trinkaus2, John F DiPersio1, Peter Westervelt1, Rizwan Romee3.   

Abstract

T cell replete HLA-haploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplant cyclophosphamide was originally described using a reduced-intensity conditioning (RIC) regimen. Given that myeloablative conditioning (MAC) is more effective at preventing disease relapse, we compared outcomes of patients receiving MAC and RIC regimens. We evaluated overall survival (OS), disease-free survival (DFS), relapse, nonrelapse mortality (NRM), and graft-versus-host disease (GVHD) of 148 patients that underwent haplo-HCT with either MAC (n = 61) or RIC (n = 87). Propensity score adjustment (PSA) was used to balance baseline characteristics between groups and more effectively compare outcomes based on conditioning intensity. After the PSA analysis, relapse was significantly decreased with MAC (hazard ratio [HR], .47; 95% confidence interval [CI], .31 to .70), but was associated with higher NRM (HR, 1.74; 95% CI, 1.13 to 2.67). OS and DFS were not significantly different between groups (HRs for MAC versus RIC were .87 [95% CI, .64 to 1.18] and .90 [95% CI, .68 to 1.18] for OS and DFS, respectively). Rates of acute and chronic GVHD were not significantly different between groups. This analysis suggests that both MAC and RIC regimens are effective in haplo-HCT and that MAC regimens may result in less relapse in selected patients. These results need to be verified in a larger registry study.
Copyright © 2018 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Conditioning intensity; Haploidentical transplantation; Myeloablative; Post-transplant cyclophosphamide; Reduced intensity

Mesh:

Substances:

Year:  2018        PMID: 29803753      PMCID: PMC7054009          DOI: 10.1016/j.bbmt.2018.05.024

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  38 in total

1.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Authors:  Madan Jagasia; Mukta Arora; Mary E D Flowers; Nelson J Chao; Philip L McCarthy; Corey S Cutler; Alvaro Urbano-Ispizua; Steven Z Pavletic; Michael D Haagenson; Mei-Jie Zhang; Joseph H Antin; Brian J Bolwell; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Robert Peter Gale; Vikas Gupta; Stephanie J Lee; Mark Litzow; Daniel J Weisdorf; Mary M Horowitz; Theresa Hahn
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

2.  Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

Authors:  Shannon R McCurdy; Yvette L Kasamon; Christopher G Kanakry; Javier Bolaños-Meade; Hua-Ling Tsai; Margaret M Showel; Jennifer A Kanakry; Heather J Symons; Ivana Gojo; B Douglas Smith; Maria P Bettinotti; William H Matsui; Amy E Dezern; Carol Ann Huff; Ivan Borrello; Keith W Pratz; Douglas E Gladstone; Lode J Swinnen; Robert A Brodsky; Mark J Levis; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

3.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

4.  High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Authors:  Leo Luznik; Javier Bolaños-Meade; Marianna Zahurak; Allen R Chen; B Douglas Smith; Robert Brodsky; Carol Ann Huff; Ivan Borrello; William Matsui; Jonathan D Powell; Yvette Kasamon; Steven N Goodman; Allan Hess; Hyam I Levitsky; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

5.  A scheme for defining cause of death and its application in the T cell depletion trial.

Authors:  Edward Copelan; James T Casper; Shelly L Carter; Jo-Anne H van Burik; David Hurd; Adam M Mendizabal; John E Wagner; Saul Yanovich; Nancy A Kernan
Journal:  Biol Blood Marrow Transplant       Date:  2007-12       Impact factor: 5.742

6.  Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.

Authors:  Krzysztof Mrózek; Guido Marcucci; Deedra Nicolet; Kati S Maharry; Heiko Becker; Susan P Whitman; Klaus H Metzeler; Sebastian Schwind; Yue-Zhong Wu; Jessica Kohlschmidt; Mark J Pettenati; Nyla A Heerema; AnneMarie W Block; Shivanand R Patil; Maria R Baer; Jonathan E Kolitz; Joseph O Moore; Andrew J Carroll; Richard M Stone; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

7.  Defining the intensity of conditioning regimens: working definitions.

Authors:  Andrea Bacigalupo; Karen Ballen; Doug Rizzo; Sergio Giralt; Hillard Lazarus; Vincent Ho; Jane Apperley; Shimon Slavin; Marcelo Pasquini; Brenda M Sandmaier; John Barrett; Didier Blaise; Robert Lowski; Mary Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-01       Impact factor: 5.742

8.  Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide.

Authors:  Luca Castagna; Roberto Crocchiolo; Sabine Furst; Stefania Bramanti; Jean El Cheikh; Barbara Sarina; Angela Granata; Elisa Mauro; Catherine Faucher; Bilal Mohty; Samia Harbi; Christian Chabannon; Carmelo Carlo-Stella; Armando Santoro; Didier Blaise
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-13       Impact factor: 5.742

9.  Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Victor Mulanovich; Rima M Saliba; Ulas D Bayraktar; Ying Jiang; Roland Bassett; Sa A Wang; Marina Konopleva; Marcelo Fernandez-Vina; Nivia Montes; Doyle Bosque; Julianne Chen; Gabriela Rondon; Gheath Alatrash; Amin Alousi; Qaiser Bashir; Martin Korbling; Muzaffar Qazilbash; Simrit Parmar; Elizabeth Shpall; Yago Nieto; Chitra Hosing; Partow Kebriaei; Issa Khouri; Uday Popat; Marcos de Lima; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2012-07-11       Impact factor: 5.742

Review 10.  Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.

Authors:  Peter C Austin; Elizabeth A Stuart
Journal:  Stat Med       Date:  2015-08-03       Impact factor: 2.373

View more
  5 in total

1.  How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide.

Authors:  Shannon R McCurdy; Leo Luznik
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Risk factors for adverse outcomes following haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: a two-center analysis.

Authors:  Viviane Jesus Torres de Lima; Anderson Felipe da Silva; Lucila Nassif Kerbauy; Mariana Nassif Kerbauy; Decio Lerner; Marta Colares; Andreza Alice Feitosa Ribeiro; Cinthya Feitosa da Silva; Nelson Hamerschlak; Leonardo Javier Arcuri
Journal:  Ann Hematol       Date:  2022-05-16       Impact factor: 4.030

3.  Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.

Authors:  Jonathan A Webster; Leo Luznik; Hua-Ling Tsai; Philip H Imus; Amy E DeZern; Keith W Pratz; Mark J Levis; Ivana Gojo; Margaret M Showel; Gabrielle Prince; Javier Bolaños-Meade; Lukasz P Gondek; Gabriel Ghiaur; W Brian Dalton; Tania Jain; Ephraim J Fuchs; Douglas E Gladstone; Christian B Gocke; Syed Abbas Ali; Carol Ann Huff; Ivan M Borrello; Lode Swinnen; Nina Wagner-Johnston; Richard F Ambinder; Richard J Jones; B Douglas Smith
Journal:  Blood Adv       Date:  2020-10-27

4.  Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study.

Authors:  Yu-Qian Sun; Ting-Ting Han; Yu Wang; Chen-Hua Yan; Feng-Rong Wang; Zhi-Dong Wang; Jun Kong; Yu-Hong Chen; Huan Chen; Wei Han; Yao Chen; Yuan-Yuan Zhang; Xiao-Hui Zhang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

5.  How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide.

Authors:  Shannon R McCurdy; Leo Luznik
Journal:  Blood       Date:  2019-11-21       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.